Ovarian cancer |
Cisplatin, doxorubicin |
Response rate lower in GSTP1-positive patients |
[85,86,87] |
Glioma |
Cisplatin, irinotecan |
GSTP1 is overexpressed in resistant tumors |
[88,89] |
Gastric cancer |
Fluorouracil (5-FU), cisplatin |
GSTP1 is overexpressed in resistant tumors |
[90] |
Prostate cancer |
Doxorubicin |
GSTP1 is overexpressed in resistant tumors |
[91] |
Breast cancer |
Adriamycin |
GSTP1 is overexpressed in resistant tumors |
[92] |
Breast cancer |
Adriamycin |
Increased apoptosis and DNA damage upon GSTP1 knockdown |
[93] |
Esophageal squamous cancer cells |
Cisplatin |
Synergistic effect of GSTP1 knockdown and cisplatin treatment |
[94] |
Lung cancer stem cells |
Cisplatin |
Synergistic effect of GSTP1 inhibition and cisplatin treatment |
[95] |
Lung cancer |
Camptothecin |
Increased apoptosis upon GSTP1 knockdown and camptothecin treatment |
[96] |
Lung cancer stem cells |
Cisplatin |
miRNA-mediated inhibition of GSTP1 reverses cisplatin resistance |
[105] |